- Home
- NBY vs TOVX Comparison
NBY vs TOVX Comparison
Compare NBY & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBY
- TOVX
- Stock Information
- Founded
- NBY 2000
- TOVX 2001
- Country
- NBY United States
- TOVX United States
- Employees
- NBY N/A
- TOVX N/A
- Industry
- NBY
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- NBY
- TOVX Health Care
- Exchange
- NBY Nasdaq
- TOVX Nasdaq
- Market Cap
- NBY 3.3M
- TOVX 3.5M
- IPO Year
- NBY 2007
- TOVX 2006
- Fundamental
- Price
- NBY $0.53
- TOVX $1.21
- Analyst Decision
- NBY Strong Buy
- TOVX Strong Buy
- Analyst Count
- NBY 1
- TOVX 1
- Target Price
- NBY $0.85
- TOVX $6.00
- AVG Volume (30 Days)
- NBY 77.8K
- TOVX 102.1K
- Earning Date
- NBY 11-07-2024
- TOVX 11-12-2024
- Dividend Yield
- NBY N/A
- TOVX N/A
- EPS Growth
- NBY N/A
- TOVX N/A
- EPS
- NBY N/A
- TOVX N/A
- Revenue
- NBY $13,844,000.00
- TOVX N/A
- Revenue This Year
- NBY N/A
- TOVX N/A
- Revenue Next Year
- NBY $26.04
- TOVX N/A
- P/E Ratio
- NBY N/A
- TOVX N/A
- Revenue Growth
- NBY 15.40
- TOVX N/A
- 52 Week Low
- NBY $0.36
- TOVX $1.14
- 52 Week High
- NBY $10.15
- TOVX $17.00
- Technical
- Relative Strength Index (RSI)
- NBY 35.25
- TOVX 37.37
- Support Level
- NBY $0.52
- TOVX $1.15
- Resistance Level
- NBY $0.58
- TOVX $1.34
- Average True Range (ATR)
- NBY 0.03
- TOVX 0.07
- MACD
- NBY -0.00
- TOVX 0.01
- Stochastic Oscillator
- NBY 11.56
- TOVX 7.41
About NBY NovaBay Pharmaceuticals Inc.
NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically eyecare and skincare products. Its product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is laboratory tested to have broad antimicrobial properties as it removes foreign material including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available directly to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease. It has two reportable segments: Eyecare and Wound Care and Skincare.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.